Warfarin-Aspirin Symptomatic Intracranial Disease Study "WASID"

Completed

Phase 3 Results

Results

For the primary endpoints; there was 4.3% rate of death in the aspirin group and a 9.7% rate in the warfarin group (P=0.02); there was a 3.2% rate of major hemorrhage in the aspirin group and a 8.3% rate in the warfarin group (P=0.01); and there was a 2.9% rate of myocardial infarction or sudden death in the aspirin group vs. a 7.3% rate in the warfarin group (P=0.02). For all vascular deaths, there was a 3.2% rate in the aspirin group and a .9% rate in the warfarin group (P=0.16). The primary end point occurred in 22.1 percent of the patients in the aspirin group and 21.8 percent of those in the warfarin group (P=0.83).